New Research Suggests Ways to Improve Cancer Therapy

	Tweet

A new glimpse at how cells respond to certain chemotherapy drugs may help clinicians understand why some tumors re-grow after treatment – and why drugs that block blood vessel formation might be a useful partner in halting this devastating effect.

Some chemotherapy drugs shrink tumors at first, but their action can also spur the bone marrow to produce cells called CEPs, which rush to the site of the cancer to help rebuild the tumor’s blood supply, according to the study published in the September issue of the journal Cancer Cell.

But in their experiments with mice and human cancer cells, Dr. Yuval Shaked of the Rappaport Faculty of Medicine at the Technion-Israel Institute of Technology and an international team of researchers discovered that not all chemo drugs have this effect on CEPs. 

For instance, paclitaxel, a drug most often used to treat lung, ovarian and breast cancer, appears to mobilize CEPs and promote new blood vessel growth in treated tumors. But gemcitabine, a chemo drug used to treat non-small cell lung cancer, pancreatic cancer, breast cancer, and bladder cancer, does not trigger increased CEP activity, the researchers found.

The difference could explain why a combination of chemotherapy and antiangiogenic drugs—drugs that block new blood vessel formation—prevent the regrowth of some tumors but fail to have any effect on other tumors, explained senior author Robert S. Kerbel of the University of Toronto.

Antiangiogenic drugs appear to be most effective when they team up with chemotherapies that unleash CEPs, the researchers suggest, since they can blunt the effects on new blood vessel growth prompted by the cells.

In fact, the results indicate that an antiangiogenic drug given “immediately prior” to a chemotherapy drug that causes a spike in CEPs can shrink tumors and kill off tumor cells, said Shaked, who completed the study at Sunnybrook Health Sciences Centre in Toronto, Canada.

But “little or no enhanced antitumor activity is obtained when it is combined with a chemotherapy drug that does not induce such a CEP spike,” the researchers note in the study.

The researchers also identified key elements of the molecular pathway that links certain chemo drugs to the mobilization of CEPs. By targeting one part of the pathway with particular antibodies in mice, “we can blunt the chemotherapy-induced CEP spike,” Shaked said. If a similar antibody could be developed for clinical use in humans, it might improve the antitumor capabilities of some chemotherapies, he explained.

Dr. Shanin Rafii, a professor of genetic medicine at Weill Medical College of Cornell University in New York City and one of the pioneers of CEP research, said the Cancer Cell study is a “huge advance” that will give clinicians a much needed way to detect how tumors respond to certain chemotherapies.

Rafii said that the research may someday lead to a simple blood draw for cancer patients, “a test that you can do noninvasively, to judge how well a chemotherapy agent is targeting angiogenesis” in a tumor. With that information in mind, clinicians could combine antitumor drugs “in a much more logical manner,” he noted.

The Technion-Israel Institute of Technology is Israel’s leading science and technology university. Home to the country’s winners of the Nobel Prize in science, it commands a worldwide reputation for its pioneering work in nanotechnology, computer science, biotechnology, water-resource management, materials engineering, aerospace and medicine. The majority of the founders and managers of Israel’s high-tech companies are alumni. Based in New York City, the American Technion Society (ATS) is the leading American organization supporting higher education in Israel, with 22 offices around the country.

Source: American Technion Society

RELATED STORIES:
Creating New Life Forms That May Help Eradicate Cancer Affecting Women   Rare abdominal cancer diagnosis being looked at in a different manner   Discovery Could Bring New Metastatic Cancer Treatments   March is National Professional Social Work Month   Cancer: “Primitive” Gene Discovered   Aiding cancer therapy by mathematically modeling tumor-immune interactions   Diet and cancer prevention: New evidence for the protective effects of fruits and veggies   Music-based “Play” Helps Young Cancer Patients Cope   How Infection and Inflammation Can Lead to Cancer   Botox Could Help Target Resistant Tumors for Treatment   Novel light-sensitive compounds show promise for cancer therapy   CT scans: Too much of a good thing can be risky   Aspirin reduces overall cancer and mortality rates   New cell findings have implications for cancer, immune disorders   Back to School Program Helps Kids with Cancer   Jews who survived wartime Europe have more cancer   Evidence strengthens link between NSAIDs and reduced cancer metastasis   Promise for Treatment of Renal Cell Cancer   Study reveals differences in cancer stage presentation between rural and urban patients   Association of quantity of alcohol and frequency of consumption with cancer mortality   New Algorithm Matches Tumor Cells to Best Anticancer Treatments   Genome study shows what cancers have in common

Comments

[ + Post Your Own ]

Now you're in the public comment zone. What follows is not Armenian Medical Network's stuff; it comes from other people and we don't vouch for it. A reminder: By using this Web site you agree to accept our Terms of Service. Click here to read the Rules of Engagement.

There are no comments for this entry yet. [ + Comment here + ]